Compare

DSM-Firmenich AG/€DSFIR

1D1W1M3M6MYTD1Y5YMAX

About DSM-Firmenich AG

DSM-Firmenich AG, established in May 2023 through the merger of Dutch company DSM N.V. and Swiss company Firmenich SA, operates in the nutrition, health, and beauty industries. The company is organized into four segments: Perfumery & Beauty, offering fragrance solutions; Taste, Texture & Health, providing food and beverage ingredients; Health, Nutrition & Care, delivering dietary supplements and medical nutrition products; and Animal Nutrition & Health, supplying animal feed ingredients. Headquartered in Kaiseraugst, Switzerland, and Maastricht, Netherlands, DSM-Firmenich has operations in nearly 60 countries and employs approximately 30,000 people. The merger combines DSM's expertise in health and nutrition with Firmenich's capabilities in perfumery and taste, positioning the company to offer integrated solutions across its sectors. (,)
Ticker
€DSFIR
Sector
Materials
Primary listing
AEX
Employees
20,786
Headquarters
Kaiseraugst, Switzerland
Website
www.dsm-firmenich.com

DSM-Firmenich AG Metrics

BasicAdvanced
€27B
-
-€5.56
0.56
€2.50
0.79%

What the Analysts think about DSM-Firmenich AG

Analyst ratings (Buy, Hold, Sell) for DSM-Firmenich AG stock.
Analyst projections of the future price of DSM-Firmenich AG stock.

Bulls say / Bears say

Second-quarter like-for-like sales grew 6%, and adjusted EBITDA beat expectations; management now expects 2026 growth at the top end of its 2–4% range. This points to resilient, volume-led demand across the business. (Reuters)
The company is applying AI to its extensive sensory-science data to design new scent and flavour molecules. If successful, this could speed up product discovery and help it develop more differentiated ingredients for customers. (DSM-Firmenich)
A €100 million savings programme and sequential margin improvement give the company levers to lift profitability beyond current levels. Management is targeting an adjusted EBITDA margin of around 20% in 2026, with a further step-up in 2027. (DSM-Firmenich)
Management expects fragrance growth to moderate towards a more normal industry pace in the second half. That could cool a key source of recent momentum even as the company targets full-year sales growth at the upper end of its range. (Reuters)
Cash conversion was 7% in the first half, below the 11–12% full-year target. The company therefore needs a much stronger second half to meet its cash-generation goal. (DSM-Firmenich)
The restructuring plan carries about €100 million in exceptional costs for expected annual savings of the same amount, alongside around 1,000 job cuts. Delays or disruption to the programme could defer margin gains or weaken execution. (DSM-Firmenich)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.

DSM-Firmenich AG Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

DSM-Firmenich AG Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing DSM-Firmenich AG

AllEURUSDGBP
Funds
Fund name
Fund size
€DSFIR weighting
iShares STOXX Europe 600 Food & Beverage€EXH3
€319M4.07%
iShares AEX€IAEX
€781M2.14%
iShares AEX£IAEX
€781M2.14%
SPDR MSCI World Materials€WMAT
$206M0.68%
HSBC MSCI Europe Islamic Screened$HIEU
€144M0.65%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.